TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Applications for Model Validation for Antiepileptogenic and Resistant Epilepsy Therapies Requested

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) requests applications for model validation for antiepileptogenic and resistant epilepsy therapies.*

The goal of this request for applications (RFA) is to validate proposed models of pharmacoresistant epilepsy and/or antiepileptogenic models for use in drug recovery. It will establish baseline data and introduce new methods for evaluating the therapeutic potential of novel compounds for epilepsy treatment.

Potential areas of research interest include studies to: test validation of proposed models for pharmacoresistance and/or antiepileptogenesis; identify therapies that can modify the progression of disease leading to chronic epilepsy; validate models that incorporate processes involved in epileptogenesis as potential research tools; develop antiepileptogenic or intervention models that allow the measurement of a block or delay in development of chronic epilepsy in adult or pediatric populations; and develop alternative models that may increase the range of anticonvulsant treatments identified and may more closely reflect the course of resistance and epileptogenesis.


For more information, potential applicants should contact Captain James Stables, Program Director, Technology Development Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2106, Bethesda, MD 20892; telephone: 301-496-1846; fax: 301-402-2157; e-mail:

*For a more detailed description of this request for applications, please visit the NIH web site at: